CRISPR Therapeutics AG (NASDAQ:CRSP) CEO Samarth Kulkarni sold 1,500 shares of the stock in a transaction that occurred on Wednesday, August 4th. The shares were sold at an average price of $125.02, for a total transaction of $187,530.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Samarth Kulkarni also recently made the following trade(s):
- On Tuesday, June 15th, Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock. The shares were sold at an average price of $126.43, for a total value of $3,792,900.00.
CRISPR Therapeutics stock traded up $3.25 during mid-day trading on Friday, hitting $136.74. The company's stock had a trading volume of 2,325,061 shares, compared to its average volume of 1,773,978. CRISPR Therapeutics AG has a 52-week low of $76.71 and a 52-week high of $220.20. The firm has a market cap of $10.42 billion, a P/E ratio of 26.76 and a beta of 2.25. The stock's 50 day moving average is $130.33.
CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Thursday, July 29th. The company reported $9.44 earnings per share for the quarter, beating analysts' consensus estimates of $3.52 by $5.92. CRISPR Therapeutics had a return on equity of 24.08% and a net margin of 49.52%. As a group, analysts predict that CRISPR Therapeutics AG will post 4.98 earnings per share for the current year.
Several analysts have recently weighed in on CRSP shares. Citigroup upgraded CRISPR Therapeutics from a "sell" rating to a "neutral" rating and upped their price objective for the company from $55.00 to $132.00 in a report on Monday, June 14th. Evercore ISI raised shares of CRISPR Therapeutics to an "outperform" rating in a report on Thursday, May 13th. Chardan Capital lowered their price objective on shares of CRISPR Therapeutics from $175.00 to $171.00 and set a "buy" rating on the stock in a research note on Friday, July 30th. raised shares of CRISPR Therapeutics from a "sell" rating to a "neutral" rating and increased their target price for the company from $55.00 to $132.00 in a research note on Monday, June 14th. Finally, Barclays raised their target price on shares of CRISPR Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a report on Wednesday, April 21st. Two analysts have rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of "Buy" and a consensus price target of $159.50.
A number of hedge funds have recently added to or reduced their stakes in the business. Slow Capital Inc. grew its holdings in shares of CRISPR Therapeutics by 0.5% during the 1st quarter. Slow Capital Inc. now owns 16,387 shares of the company's stock valued at $2,369,000 after acquiring an additional 87 shares in the last quarter. Golden Green Inc. grew its stake in CRISPR Therapeutics by 5.4% in the second quarter. Golden Green Inc. now owns 1,758 shares of the company's stock valued at $285,000 after purchasing an additional 90 shares in the last quarter. V Wealth Advisors LLC grew its stake in CRISPR Therapeutics by 6.0% in the first quarter. V Wealth Advisors LLC now owns 1,775 shares of the company's stock valued at $216,000 after purchasing an additional 100 shares in the last quarter. Spectrum Planning & Advisory Services Inc. increased its position in CRISPR Therapeutics by 2.2% in the 1st quarter. Spectrum Planning & Advisory Services Inc. now owns 4,675 shares of the company's stock worth $570,000 after purchasing an additional 100 shares during the last quarter. Finally, Montag A & Associates Inc. raised its stake in shares of CRISPR Therapeutics by 2.5% during the 2nd quarter. Montag A & Associates Inc. now owns 4,194 shares of the company's stock worth $679,000 after purchasing an additional 102 shares in the last quarter. Institutional investors own 55.43% of the company's stock.
About CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Featured Article: What are catch-up contributions?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.